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Introduction References Cont.’
Signs &Symptoms
Signs and symptoms may vary person to 
person depending on the level of residual 
VWF activity, the classification group VWD 
that the individual has and age and sex 
may play a role in the severity of signs and 
symptoms to some extent (Leebeek, 
Eikenboom, 2016). Type one is the most 
common type of VWD seen in individuals 
(CDC, 2016).   Signs and symptoms are 
• Nosebleeds; individuals may 
experience five or more nosebleeds 
in a year, that happen for no reason 
without injury. They last for long 
periods of time; usually more than 
10 minutes and may need packing or 
cauterized to cease the nosebleed. 
• Easy bruising; frequent bruising that 
happens with mild trauma.  
Hematomas that are diffused in a 
large surface area usually larger than 
the size of a quarter.
• Heavy menstrual cycles in women; 
heavy bleeding and passing of large 
clots during menstrual cycles.  
Women and adolescents with VWD 
may notice that they are soaking 
through two or more pads or 
tampons in a two-hour period. 
• Mucocutaneous bleeding lasting 
more than five minutes from small 
lacerations. Post-surgical areas and 
prolonged bleeding after childbirth.   
Oozing of blood after dental work / 
dental extractions.
• In type 2N and type 3, joint bleeding 
maybe a complication (Leebeek, 
Eikenboom, 2016). 
• Gastrointestinal bleeding is a 
possible severe clinical manifestation 
that individuals may experience. 
Although VWD is the most common 
inherited blood disease, many healthcare 
providers are unfamiliar about the 
disorder.  While researching VWD, this 
nurse has gain knowledge that can assist in 
identifying patients that may be suffering 
from VWD.  This nurse sought out to 
investigate a blood disorder due to a 
personal affiliation with a child that were 
experiencing similar signs and symptoms of 
VWD.  VWD is a disorder that although 
complications can occur, many individuals 
that suffer from VWD can lead a normal 
life with the right education and resources.  
The topic that this nurse has chosen to 
investigate and present is a bleeding 
condition called von Willebrand Disease 
(VWD).  This nurse has a child, which is a 
college endurance athlete that has been 
experiencing health issues such as Iron 
Deficiency Anemia. When searching blood 
disorders and their pathophysiology, VWD 
was the one condition that became .  VWD 
is one of the most prevalent inherited 
bleeding disorder (James, 2017).  This 
disorder is the result of a low levels of von 
Willebrand factor (VWF). VWF is a protein 
that binds to factor VIII; an essential 
clotting protein and platelets in the blood 
vessel walls that aids in production of a 
platelet plug during the clotting process 
(National Hemophilia Foundation, n.d.).   
This disorder was first described in 1926 by 
Erik von Willebrand.  He distinguished that 
it differed from hemophilia and named it 
“pseudo hemophilia”.
Three main types of VWD exist, which is 
based on the VWF; type 1 VWD, type 2 
VWD and type 3 VWD (National Hemophilia 
Foundation, n.d.).   On rare incidences, a 
fourth type of VWD can developed from 
other medical conditions; lymphoma’s, 
leukemia’s, disorder such as lupus and 
certain medications (Nordqvist, 2016).  
Type 1 is found in 60-80 % of individuals, 
there is an insufficient amount of VWF in 
the blood and symptoms are usually mild.  
Type 2 is found in 15-30 % of patients and 
symptoms range from mild to moderate. 
Type 3 is five to ten percent of with VWD 
and there is a complete deficiency of VWF.  
This type displays the most severe 
symptoms (Federici, 2016, p. 42).  VWD 
equally affects men, women and children. 
According to James (2017), “90% of women 
being treated at hemophilia centers in the 
U.S. have VWD” (p. 21).There is also no 
geographical or ethnic affiliation with VWD 
(Lillecrap, 2013). Inheritance of VWD 
happens by way of autosomal dominant or 
autosomal recessive patterns.  This 
disorder is the result of a low levels of von 
Willebrand factor (VWF). Chromosome 12 
is the carrier of VWD.  Symptoms of the 
disorder vary from mild to severe. This can 
make the diagnosis of VWD difficult in 
individuals with mild symptoms to be 
made.  In many cases, individuals with mild 
symptoms go undiagnosed.  Type 1 VWD is 
characterized by a short supply of VWF 
with normal structure and function.  Type 
2, is broken down into four different types 
according to the defect of VWF; 2A, 2B, 2M 
and 2N.  Type 3 there is no functioning 
VWF (Swystun, James, 2016).   
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• Evaluating patients is to obtain a 
complete family history:  It is 
important to know unnoticed mild 
symptoms, a family history of VWD 
or abnormal bleeding may not always 
be apparent
• Educate patients and their family 
members on VWD: how to decrease 
the risk of injury, steps needed to 
take to ensure patient safety during  
bleeding episodes. Discuss the 
importance of informing all 
healthcare about their diagnosis and 
type of VWD disease. 
• Talk with the patient and family inn 
regards about notifying any sports 
coach about their (Nordqvist, 2016).
• Be educated on resources that are 
available to patients and family 
members such as; Hemophilia 
treatment centers, genetic 
counseling, physical therapist if joint 
bleeding is a complication and 
hematologist 
• Educate patients to consult their 
physicians before taking over the 
counter (OTC) medications such as 
Aspirin, Ibuprofen and other NSAIDS 
that may hinder blood clotting 
(Nordqvist, 2016 section 7).  
• Be familiar with VWD and the steps 
to guarantee hemostasis and 
decrease risk of complications 
related to VWD
• A Complete blood count, activated 
partial thromboplastin time (aPTT), 
prothrombin time (PT), fibrinogen 
level and platelet counts are 
important lab values that should be 
observed.
• Additional test VWF antigen (VWF: 
Ag), VWF ristocetin cofactor (VWF: 
RCO) and a factor VIII level 
• Treatment for VWD is based on 
normalizing VWF and factor VIII 
levels, this is achieved by using 
medicines such as Desmopressin 
(DDAVP) or infusing exogenous 
coagulation factors such as high 
purity factor VIII VWF. VWF-factor 
VIII or VWF concertation or 
tranexamic acid is used in type 3 
(Leebeek, Eikenboom, 2016)
• Birth control containing estrogen 
can aid in HMB in women
• Encourage a well-balanced healthy 
diet with exercise. Advise children 
with VWD to avoid contact sports 
that would increase the risk of injury 
(Nordqvist, 2016)
Implications of 
Nursing
Type 3 VWD has a heterozygous 
mutational basis consisting of 80 or more 
variegated mutations, which would include 
VWF gene insertions, missense mutation 
and partial to total VWF gene deletions 
(Swystun, James, 2017).  
In 35% of cases with type 1 VWD, no 
identifiable VWF mutations, this leads to 
looking at other identifiable VWF 
mutations:  One theory is the contributor to 
quantitative variation of VWF and the ABO 
blood group.  VWF levels is noted to be 
25% lower on individuals of “O” blood type 
(Lillicrap, 2017).  In acquired VWD, the 
most common causes include: Cardiac 
disorders; aortic stenosis being the most 
prevalent, lymphoproliferative diseases, 
hypothyroidism, drug related and systemic 
lupus erythematous (Hassan et al. 2013). 
• Women with VWD also suffer other 
forms of abnormal reproductive 
bleeding such as bleeding with 
ovulation resulting in a hemorrhagic 
ovarian cyst or peritoneal cavity 
bleeding.
• Antepartum bleeding, postpartum to 
severe postpartum hemorrhage, and 
perineal hematoma’s increased by two 
to ten-fold in women with VWD (James, 
2017)
• A threefold increase risk of 
hypothyroidism in patients with 
congenital VWD (Hassan et al., 2013)
• Gastrointestinal bleeding from 
angiodyplasia that is most commonly 
seen in elderly patients with type 2 and 
3VWD
• Increase risk for arthopathy and 
decrease joint function resulting in 
intraarticular joint bleeding.
• Patients with type 3 are at greater risk 
for joint bleeding which results in a 
lower quality of life than those of the 
general population which is associated 
with bleeding phenotype
• As a result of the physiologic rise in 
VWF levels throughout life, patients 
with type 1 may experience levels 
within normal limits when they become 
older.
• With type 2 VWD patients, the VWF 
activity remains low due to the 
functional defect in the protein, which 
causes an increased risk for bleeding 
symptoms that could occur with 
increased age.
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Pathophysiological 
Processes
Underlying
Pathophysiology
Most commonly inheritance pattern for 
VWD is autosomal dominant. Type 2A, 
2N and type 3 are known to be 
autosomal recessive (DeLong, 
Eikenboom, 2015).   The underlying 
cause of VWD lies within a qualitive or 
quantitative defect of the VWF protein 
(DeLong, Eikenboom, 2015).  “VWF is a 
high-molecular-weight glycoprotein 
with a key role in the first phase of 
hemostasis” (Casonato, Cattini, Barbon, 
Daidone, Pontara, 2015. p. 682).  VWF is 
located as stated above on the short 
arm of chromosome 12, at the locus 
12p13.3, which contains 52 exons that 
range in size from 1.3kb to 40bp 
(Swystun, James, 2015).  Endothelial 
cells and megakaryocytes play an 
important role in the circulation of VWF, 
along with storage of VWF multimers in 
cigar-shaped vesicles known as Weibel-
Palade bodies (WPBs) (Delong, 
Eikenboom, 2015).   In type 1 VWD, 
observed is a partial VWF deficiency, 
with the variant location of the VWF 
gene on the external loci and variant 
location on exon 1-52 (pg.48).  Type 2A 
VWD, is characterized by decreased 
VWF-platelet binding because of the 
deletion of high and intermediate 
molecular weight multimers (pg.51).  
Type 2B, is due to gain-of-function 
missense mutations within the Gplb 
binding site of VWF.  This causes 
unplanned VWF interactions that result 
in the depletion of high molecular 
weight (HMW) multimers and 
subsequent thrombocytopenia (pg. 51).   
Type 2M VWD is due to the decreased 
VWF platelet interactions, however, 
multimerization is normal. Mutations 
are localized to the Gplb binding site in 
the A1 andA3 domain of VWF resulting 
in a decrease in VWF binding to sub 
endothelial collagen (pg.52).  Type 2N 
VWD is initially known as autosomal 
Hemophilia A.  These individuals 
present with a low FVIII level.  This type 
of VWD is an, “homozygous or 
compound heterozygous manner, 
involving either two 2N alleles or a 2N 
and a VWF null allele” (Swytun, James, 
2017, p. 53).  Type 3 VWD is noted as 
the severe clinical phenotype with 
absent VWF in the plasma, along with 
very low factor VIII: C. In 80% of 
patients with type 3 VWD, genetic 
defects in the VWF genes are null 
alleles, which gives explanation to the 
absence of VWF in whole.  
Underlying Patho. 
Cont.’
Significance of 
Pathophysiology
• 10% of women with VWD 
experience a history of endometrial 
hyperplasia 
• Of the high occurrence of women 
that experience heavy menstrual 
bleeding (HMB) with no explanation 
has reported to range 5% to 36% 
adolescents.
Figure 1.0 Illustration of VWD in an individual
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